Jefferies Group's REGN Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 5,885 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $4.54 M, representing 0.02% of the portfolio. First purchased in 2018-Q1, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in REGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 25,535 shares. Largest reduction occurred in Q1 2025, reducing 29,199 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -19,650 | Reduce 76.95% | 5,885 | $771.87 |
| Q3 2025 | +25,535 | New Buy | 25,535 | $562.27 |
| Q2 2025 | -6,623 | Sold Out | 0 | $0.00 |
| Q1 2025 | -29,199 | Reduce 81.51% | 6,623 | $634.23 |
| Q4 2024 | +8,327 | Add 30.29% | 35,822 | $712.33 |
| Q3 2024 | +7,004 | Add 34.18% | 27,495 | $1051.24 |
| Q2 2024 | +11,851 | Add 137.16% | 20,491 | $1051.03 |
| Q1 2024 | +840 | Add 10.77% | 8,640 | $962.49 |
| Q4 2023 | +5,500 | Add 239.13% | 7,800 | $878.29 |
| Q3 2023 | -7,300 | Reduce 76.04% | 2,300 | $822.96 |
| Q2 2023 | -3,275 | Reduce 25.44% | 9,600 | $718.54 |
| Q1 2023 | +12,327 | Add 2249.45% | 12,875 | $821.67 |
| Q4 2022 | +548 | New Buy | 548 | $721.49 |
| Q1 2019 | -10,522 | Sold Out | 0 | $0.00 |
| Q4 2018 | +10,522 | New Buy | 10,522 | $373.50 |
| Q3 2018 | -11,819 | Sold Out | 0 | $0.00 |
| Q2 2018 | +6,110 | Add 107.02% | 11,819 | $344.95 |
| Q1 2018 | +5,709 | New Buy | 5,709 | $344.37 |
Jefferies Group's Regeneron Pharmaceuticals Investment FAQs
Jefferies Group first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q1 2018, acquiring 5,709 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Regeneron Pharmaceuticals, Inc. (REGN) for 18 quarters since Q1 2018.
Jefferies Group's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2025, adding 25,535 shares worth $14.36 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 5,885 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $4.54 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 35,822 shares, as reported at the end of Q4 2024.